Education
About Us
Working with TipRanks
Follow Us
Mineralys Therapeutics, Inc. (MLYS)
NASDAQ:MLYS
RESEARCH TOOLSreports
MLYS Analyst Ratings
Strong Buy
5 Buy
1 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
MLYS Stock 12 Month Forecast
Average Price Target
$37.67
▲(13.74% Upside)
| Highest Price Target$45.00 | Average Price Target$37.67 | Lowest Price Target$26.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
Bank of America Securities
$43
Buy
29.83%
Upside
Reiterated
09/04/25
Jefferies
$15→$26
Hold
-21.50%
Downside
Reiterated
09/03/25
LifeSci Capital
$44
Buy
32.85%
Upside
Reiterated
08/31/25
AstraZeneca (Nasdaq: AZN) presented detailed results from the Phase III BaxHTN study, evaluang baxdrostat in paen ts with uncontrolled and resistant hypertension, this weekend at the 2025 (data also published in NEJM). 2mg doses of the selecv e aldosterone synthase inhibitor led to placebo-adjusted SBP reducons (as measured by AOBP) of 8.7 mmHg (14.5 mmHg absolute, P<0.001) and 9.8 mmHg (15.8 mmHg absolute, P<0.001), respecv ely, at Week 12. Baxdrostat also meaningfully reduced 24-hour and ambulatory nighme SBP vs. placebo in a subset (N=56) of tested paen ts, and the 2mg dose demonstrated consistent benefit across all pre-specified subgroups (age, sex, race, uncontrolled/resistant hypertension, baseline SBP/eGFR/BMI).
Stifel Nicolaus
$45
Buy
35.87%
Upside
Reiterated
08/13/25
Wells Fargo
$26
Buy
-21.50%
Downside
Reiterated
08/13/25
H.C. Wainwright
$42
Buy
26.81%
Upside
Reiterated
08/13/25
Guggenheim
$52→$48
Buy
44.93%
Upside
Reiterated
05/13/25
Goldman Sachs
$24
Buy
-27.54%
Downside
Reiterated
03/07/25
Goldman Sachs Remains a Buy on Mineralys Therapeutics, Inc. (MLYS)Buy MLYS as we believe that the upcoming pivotal Phase 2 Advance-HTN study results for lorundrostat in uncontrolled and resistant hypertension will set an important impression for subsequent presentations and potentially outperform expectations due to the study’s state-of-the-art design features. 12m target, $24.
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
Bank of America Securities
$43
Buy
29.83%
Upside
Reiterated
09/04/25
Jefferies
$15→$26
Hold
-21.50%
Downside
Reiterated
09/03/25
LifeSci Capital
$44
Buy
32.85%
Upside
Reiterated
08/31/25
AstraZeneca (Nasdaq: AZN) presented detailed results from the Phase III BaxHTN study, evaluang baxdrostat in paen ts with uncontrolled and resistant hypertension, this weekend at the 2025 (data also published in NEJM). 2mg doses of the selecv e aldosterone synthase inhibitor led to placebo-adjusted SBP reducons (as measured by AOBP) of 8.7 mmHg (14.5 mmHg absolute, P<0.001) and 9.8 mmHg (15.8 mmHg absolute, P<0.001), respecv ely, at Week 12. Baxdrostat also meaningfully reduced 24-hour and ambulatory nighme SBP vs. placebo in a subset (N=56) of tested paen ts, and the 2mg dose demonstrated consistent benefit across all pre-specified subgroups (age, sex, race, uncontrolled/resistant hypertension, baseline SBP/eGFR/BMI).
Stifel Nicolaus
$45
Buy
35.87%
Upside
Reiterated
08/13/25
Wells Fargo
$26
Buy
-21.50%
Downside
Reiterated
08/13/25
H.C. Wainwright
$42
Buy
26.81%
Upside
Reiterated
08/13/25
Guggenheim
$52→$48
Buy
44.93%
Upside
Reiterated
05/13/25
Goldman Sachs
$24
Buy
-27.54%
Downside
Reiterated
03/07/25
Goldman Sachs Remains a Buy on Mineralys Therapeutics, Inc. (MLYS)Buy MLYS as we believe that the upcoming pivotal Phase 2 Advance-HTN study results for lorundrostat in uncontrolled and resistant hypertension will set an important impression for subsequent presentations and potentially outperform expectations due to the study’s state-of-the-art design features. 12m target, $24.
Best Analysts Covering Mineralys Therapeutics, Inc.
1 Month
xxx
Success Rate
5/10 ratings generated profit
Average Return
+13.45%
reiterated a xxx
rating 25 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 50.00% of your transactions generating a profit, with an average return of +13.45% per trade.
3 Months
xxx
Success Rate
7/10 ratings generated profit
Average Return
+26.17%
reiterated a xxx
rating 25 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 70.00% of your transactions generating a profit, with an average return of +26.17% per trade.
1 Year
Success Rate
10/10 ratings generated profit
Average Return
+99.16%
reiterated a buy rating 25 days ago
Copying Matthew Caufield's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +99.16% per trade.
2 Years
xxx
Success Rate
13/13 ratings generated profit
Average Return
+126.52%
reiterated a xxx
rating 7 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +126.52% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
MLYS Analyst Recommendation Trends
Rating
May 25
Jun 25
Jul 25
Aug 25
Sep 25
Strong Buy
17
11
12
10
7
Buy
0
0
0
0
1
Hold
8
4
2
3
3
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
25
15
14
13
11
Each month's total comprises the sum of three months' worth of ratings.
MLYS Financial Forecast
MLYS Stock Forecast FAQ
What is MLYS’s average 12-month price target, according to analysts?
Based on analyst ratings, Mineralys Therapeutics, Inc.’s 12-month average price target is 37.67.
What is MLYS’s upside potential, based on the analysts’ average price target?
Mineralys Therapeutics, Inc. has 13.74% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is MLYS a Buy, Sell or Hold?
Mineralys Therapeutics, Inc. has a consensus rating of Strong Buy which is based on 5 buy ratings, 1 hold ratings and 0 sell ratings.
What is Mineralys Therapeutics, Inc.’s price target?
The average price target for Mineralys Therapeutics, Inc. is 37.67. This is based on 6 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $45.00 ,the lowest forecast is $26.00. The average price target represents 13.74% Increase from the current price of $33.12.
The highest analyst price target is $45.00 ,the lowest forecast is $26.00. The average price target represents 13.74% Increase from the current price of $33.12.
What do analysts say about Mineralys Therapeutics, Inc.?
Mineralys Therapeutics, Inc.’s analyst rating consensus is a Strong Buy. This is based on the ratings of 6 Wall Streets Analysts.
How can I buy shares of MLYS?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.